Absci (ABSI) Change in Accured Expenses (2020 - 2025)
Absci (ABSI) reported Change in Accured Expenses of $2.5 million for Q3 2025, up 80.22% on a YoY basis from $1.4 million in Q3 2024, and up 22.87% sequentially from $2.0 million in Q2 2025.
Absci (ABSI) Change in Accured Expenses (2020 - 2025) Analysis & Trends
Absci (ABSI) has 6 years of Change in Accured Expenses data on file, last reported at $2.5 million in Q3 2025.
- For the quarter ending Q3 2025, Change in Accured Expenses rose 80.22% year-over-year to $2.5 million; the trailing twelve-month figure through Sep 2025 stood at $1.9 million (up 233.87% YoY), and the FY2024 full-year result was -$295000.0, up 75.68% from the prior year.
- Change in Accured Expenses improved to $2.5 million in Q3 2025, from $2.0 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $3.9 million in Q3 2022 to a low of -$4.5 million in Q1 2022.
- A 5-year average of -$77947.4 and a median of -$374000.0 in 2023 frame the typical range for Change in Accured Expenses.
- Across the five-year window, Change in Accured Expenses plunged 1337.23% in 2021 and soared 437.49% in 2022, its largest moves.
- Tracing ABSI's Change in Accured Expenses over 5 years: stood at $2.1 million in 2021, then tumbled by 123.28% to -$500000.0 in 2022, then advanced by 25.2% to -$374000.0 in 2023, then soared by 303.21% to $760000.0 in 2024, then jumped by 230.79% to $2.5 million in 2025.
- Business Quant data shows ABSI's Change in Accured Expenses at $2.5 million in Q3 2025, $2.0 million in Q2 2025, and -$3.4 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 469.11 Bn | 464.32 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 123.03 Bn | 115.78 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.37 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 63.44 Bn | 63.44 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Absci | 1.20 Bn | 1.07 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 2.51 Mn |
| Sep 30, 2025 | 2.51 Mn |
| Jun 30, 2025 | 2.05 Mn |
| Jun 30, 2025 | 2.05 Mn |
| Mar 31, 2025 | -3.41 Mn |
| Mar 31, 2025 | -3.41 Mn |
| Dec 31, 2024 | 760,000.00 |
| Dec 31, 2024 | 760,000.00 |
| Sep 30, 2024 | 1.40 Mn |
| Sep 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | 1.46 Mn |
| Jun 30, 2024 | 1.46 Mn |
| Mar 31, 2024 | -3.91 Mn |
| Mar 31, 2024 | -3.91 Mn |
| Dec 31, 2023 | -374,000.00 |
| Dec 31, 2023 | -374,000.00 |
| Sep 30, 2023 | 2.96 Mn |
| Sep 30, 2023 | 2.96 Mn |
| Jun 30, 2023 | -1.38 Mn |
| Jun 30, 2023 | -1.38 Mn |